

Patients with more than five brain metastases: is radiosurgery a reasonable approach?

GIUSEPPE MINNITI, MD, PHD

UPMC Hillman Cancer Center, San Pietro Hospital FBF (Rome), and UPMC Hillman Cancer Center Villa Maria, Mirabella Eclano (AV);
IRCCS Neuromed, Pozzilli (IS), Italy;




Disclosure: honoraria fees from BrainLab, Elekta, ABBVIE

✓ *Outline*

- *SRS for brain metastases*
- *How many metastases can be treated with SRS?*
- *Optimal dose/fractionation*
- *New SRS techniques for multiple brain metastases*

✓ *Whole Brain Radiation Therapy*



Late toxicity

Radiation necrosis

Normal pressure

*hydrocephalus, causing
cognitive, gait and bladder
dysfunction*

Neuroendocrine dysfunction

Cerebrovascular disease

Gamma Knife SRS



*Gamma radiation from
Cobalt-60 source
Use multiple beams
(4-18 mm)
Fixed frame SRS
High conformality
Accuracy 0.5-1mm*

CyberKnife SRS



*Industrial robot arm
with 6MV X-band linac
Use 100-2000 non-
isocentric beams
Frameless SRS/FSRS
High conformality
Accuracy 0.5-1mm
X-ray 6D IGRT*

LINAC-based SRS



*High-energy X-ray from
LINAC
Use shaped beams or
dynamic arcs
Frameless SRS/FSRS
High conformality
Accuracy 0.5-1mm
CBCT/ ExacTrac X-Ray
6D IGRT*

- ✓ *The addition of WBRT to SRS/Surgery has never been shown to not improve OS*

<i>Authors</i>	<i>Arms</i>	<i>mOS</i>	<i>P value</i>
Patchell, 1998	<i>Surgery</i>	9.9	0.39
	<i>Surgery + WBRT</i>	11.1	
Kocher, 2011	<i>SRS/Surgery</i>	10.9	0.89
	<i>SRS/Surgery + WBRT</i>	10.7	
Aoyama, 2006	<i>SRS</i>	8.0	0.42
	<i>SRS + WBRT</i>	7.5	
Chang, 2009	<i>SRS</i>	15.2	0.003
	<i>SRS + WBRT</i>	5.7	
Brown, 2016	<i>SRS</i>	10.4	0.92
	<i>SRS + WBRT</i>	7.4	


Recommendations

- *Don't routinely add adjuvant WBRT to SRS for limited brain metastases*
- *Randomized studies have demonstrated no OS benefit*
- *The addition of WBRT to SRS is associated with diminished cognitive function and worse-patient fatigue and QOL*
- *Surveillance and judicious salvage allows patients to enjoy the highest QOL without a detriment in functional status and OS*

✓ *Outline*

- *SRS for brain metastases*
- ***How many metastases can be treated with SRS?***
- *Optimal dose/fractionation*
- *New SRS techniques for multiple brain metastases*

Group	Median overall survival, months (95% CI)	HR (95% CI)	p value
— 1 tumour	13.9 (12.0–15.6)	0.76 (0.66–0.88)	0.0004
— 2–4 tumours	10.8 (9.4–12.4)	Reference	
— 5–10 tumours	10.8 (9.1–12.7)	0.97 (0.81–1.18)	0.78




Number at risk	0	6	12	18	24	30	36	42
1 tumour	455	334	234	197	161	131	101	71
2–4 tumours	531	411	315	215	161	111	81	51
5–10 tumours	208	148	108	84	61	41	31	1

Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2–9 versus 10 or more tumors


Yamamoto M et al.

Group MST (95% CI)
 — A (2-9) 6.8 (5.8-7.8) months
 B (≥10) 6.0 (5.0-7.0) months
 HR: 1.133 (95% CI; 0.975-1.320), p = 0.10

Post-SRS (mos)	Actuarial incidences (%)	
	Group A	Group B
12	28.7	26.7
24	11.3	9.0
36	5.0	3.3



No. at risk	0	6	12	18	24	30	36
A	359	194	100	59	37	23	15
B	358	175	95	46	28	14	9



Post-SRS (mos)	Actuarial incidences (%)	
	Group A	Group B
12	88.7	89.1
24	76.6	82.0
36	71.5	61.7



Group HR: 1.059 (95% CI; 0.680-1.649)
 B (≥10) p = 0.80

No. at risk	0	6	12	18	24	30	36
A	359	189	96	56	34	21	15
B	358	174	96	46	28	13	9

J Neurosurg (Suppl 2) 121:16–25, 2014

Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2–9 versus 10 or more tumors

Yamamoto M et al.




J Neurosurg (Suppl 2) 121:16–25, 2014


✓ *Patients treated for BM at UPMC San Pietro FBF January 2015 - June 2018*

• *263 patients with 1274 brain mets*

- *1 met (n= 61)*
- *2-5 mets (n= 117)*
- *6-10 mets (n= 60)*
- *> 10 mets (n= 25)*



Treatment planning in a patient with 6 mets treated with SRS



24-month post- SRS MRI


✓ *Outline*

- *SRS for brain metastases*
- *How many metastases can be treated with SRS?*
- ***Optimal dose/fractionation***
- *New SRS techniques for multiple brain metastases*


Dose-effect relation in stereotactic radiotherapy for brain metastases.

A systematic review

*RS data**






*mf-RS data**



*12 months



11 selected publications

Single-fraction vs multi-fraction SRS



Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery

Francesco Cicone · Giuseppe Minniti · Andrea Romano · Annalisa Papa · Claudia Scaringi ·
 Francesca Tavanti · Alessandro Bozzao · Riccardo Maurizi Enrici · Francesco Scopinaro




Semiquantitative PET parameter	AUC	Asymptotic significance	Standard error	95 % Confidence interval		Best differentiating cut-off value	Sensitivity (%)	Specificity (%)	Accuracy (%)
				Lower limit	Upper limit				
SUVL _{max} /Bkg _r _{max} (rSUV)	0.924	0.0001	0.065	0.798	1	1.59	93.3	90.9	91.9
rCBV	0.808	0.002	0.079	0.653	0.962	2.14	86.7	68.2	75.6

✓ *Outline*


- *SRS for brain metastases*
- *How many metastases can be treated with SRS?*
- *Optimal dose/fractionation*
- ***New SRS techniques for multiple brain metastases***

SRS for multiple brain mets



✓ *Single isocenter multiple targets technique*

Single- and multibeam geometries utilized for the single isocenter volumetric modulated arc therapy radiosurgery technique.










Conclusions: We have outlined a practical approach to cranial radiosurgery treatment planning using the single isocenter VMAT platform. One or 2 arc single isocenter plans are often adequate for treatment of single targets, while 2-4 arcs may be more advantageous for multiple targets. Given the high plan quality and extreme clinical efficiency, this single isocenter VMAT approach will continue to become more prevalent for linac-based radiosurgical treatment of 1 or more intracranial targets and will likely replace multiple isocenter techniques.

Clarke et al.

Brain Elements, version 1.5

Single-isocenter DCA SRS for multiple brain metastases





Preliminary Experience
with Brain Elements
Treatment Planning at
UPMC Hillman Cancer
Center, San Pietro
Hospital, Rome:
Evaluation of patient's
repositioning accuracy
and clinical efficacy


Table 1. Summary of patient characteristics and treatment parameters

Parameter	No
number of patients	26
median age	52
sex (F/M)	14/12.
histology	
lung	12
breast	4
melanoma	6
kidney	3
ovary	1
no of lesions per patient	
2-5 lesions	8
6-10 lesions	18
tumor location	
frontal	20%
parietal	24%
temporal	19%
cerebellar	15%
occipital	17%
radiosurgical dose	
22 Gy	55
20 Gy	115
18 Gy	11
GTV (cm³)	
mean (SD)	0.34 (0.56)
median	0.29
range	0.17-4.86
total volume	2.2
PTV (cm³)	
mean (SD)	0.60 (0.7)
median	0.54
range	0.27-5.92
total volume	3.7
Conformity index	
median	1.27
range	1.07-1.55
Gradient index	
median	3.92
range	2.78-5.56
D95 (%)	
mean (SD)	97.7 (4.5)
median	97.8 (91.6-107)
V95 (%)	
mean (SD)	99.7 (1.1)
median	99.5 (92.4-101)



Preliminary Experience with Brain Elements Treatment Planning at UPMC Hillman Cancer Center, San Pietro Hospital, Rome: Evaluation of patient's repositioning accuracy and clinical efficacy




SIMT-DOA SRS for multiple brain mets



SIMT DCA SRS for multiple brain mets (n=10)






Pre-SRS





6 months after SRS

Preliminary Experience with Brain Elements Treatment Planning at UPMC Hillman Cancer Center, San Pietro Hospital, Rome:

Clinical outcomes






Preliminary Experience with Brain Elements Treatment Planning at UPMC Hillman Cancer Center, San Pietro Hospital, Rome: Evaluation of patient's repositioning accuracy and clinical efficacy



Single-Isocenter Multiple-Target Stereotactic Radiosurgery: Risk of Compromised Coverage

Justin Roper, PhD,* Vorakarn Chanyavanich, PhD,*
 Gregory Betzel, PhD,* Jeffrey Switchenko, PhD,[†]
 and Anees Dhabaan, PhD*






Table 2. Effect of residual isocenter deviations evaluated by the ExacTrac kV X ray 6D imaging system on geometric and dosimetric accuracy of SRS treatment

Parameter	mean distance from isocenter (SD)	x (lateral)	y (vertical)	z (longitudinal)	3D vector	Pitch (x)	Yaw (y)	Roll (z)	Non-overlapping GTV volume %	Non-overlapping PTV volume %	V95 variation %	Mean dose variation %
mean	34.7	-0.085	0.156	-0.23	0.42	-0.13	-0.08	0.1	12.6 [^]	6.1 [*]	1.34 ^{**}	0.7
SD	17.1	0.3	0.25	0.44	0.30	0.28	0.25	0.32	19	10	2.3	1.2
range	0.22 - 76.3	-0.41 - 0.49	-0.46-0.38	-0.48-0.5	0.05-0.8	-0.42-0.48	-0.4-0.4	-0.5-0.5	0-58	0-44	0-9.2	0-4



Preliminary Experience with Brain Elements Treatment Planning at UPMC Hillman Cancer Center, San Pietro Hospital, Rome:

- Impact of isocenter residual errors on target geometry and dosimetry


Preliminary Experience with Brain Elements Treatment Planning at UPMC Hillman Cancer Center, San Pietro Hospital, Rome:

- **V95 < 95% in 25 targets**
- ✓ Correlation with distance from plan isocenter and target volume

Target coverage maintained in all targets with the addition of GTV-to-PTV margin of 1 mm



Single-isocenter multi-target DCA SRS







large GTV geometric variations (blue area and orange area) as result of translational and rotational isocenter residual errors.

Risk of radiation-induced brain necrosis

Estimated risk of RN

12-month 9% (3%)
24-month 14% (5%)




Pre-SRS

Post- 12 m

Post- 18 m


Margins add a significant amount of normal tissue to the treatment volume.



GTV = 1.3 cc

PTV 1mm = 1.9 cc ($V_{12\text{ Gy}}$ 4.7 cc)

PTV 2mm = 2.8 cc ($V_{12\text{ Gy}}$ 8.4 cc)



1-year risk of radionecrosis was 24% for $V_{12\text{ Gy}}$ of 6.0-10.9 cm^3 and 51% for $V_{12\text{ Gy}} >10.9 \text{ cm}^3$, respectively.


Preliminary Experience with Brain Elements Treatment Planning at UPMC Hillman Cancer Center, San Pietro Hospital, Rome:

Table 3. Target loss coverage ($v_{95} < 95\%$) according to the size and the distance from isocenter

Parameter	Distance from isocenter < 3.9 cm		Distance from isocenter \geq 3.9 cm	
	< 0.29 mm	\geq 0.29mm	< 0.29 mm	\geq 0.29 mm
Size of GTV				
1 mm GTV-to-PTV margins	0	0	0	0
0.5 mm GTV-to-PTV margins	2	0	4	1
No GTV-to-PTV margins	6	1	16	2

Accuracy of treatment: loss target coverage ($V_{95} < 95\%$)

Single-isocenter multiple-targets SRS technique




↑ GTV-to-PTV 1 mm

↑ GTV-to-PTV 0.5 mm



↑ GTV-to-PTV 0 mm

SIMT DCA SRS for multiple brain mets (n=21)

D SPGR
axial




>> DVH




Coronal

H




Sagittal

H



Gy



Preliminary Experience with Elements at UPMC Hillman Cancer Center, San Pietro Hospital, Rome

Factors correlated with the risk of neurotoxicity

Sex	lesions (n)	Dp (Gy)	Volume GTV	Vol Tot PTV (cm3)	V12 Brain	V10 Brain	V8 Brain	V5 Brain
M	6	20	1,3	2,1	7,10	9,60	13,80	32,62
F	9	20	3,9	6,8	21,70	29,80	45,10	88,70
M	9	22	2,6	4,2	15,80	21,58	33,28	78,00
M	5	22	1,4	2,3	10,40	14,30	20,40	45,20
F	8	20	8,9	13,1	46,80	64,80	94,80	204,00
M	10	22	2,6	4,1	15,60	20,80	31,90	72,80
M	9	22	1,7	2,7	10,10	13,20	19,90	49,4
M	5	20	1,4	2,1	5,70	7,90	11,70	25,40
F	6	22	3,9	6,4	17,50	22,30	33,70	68,70
F	5	22	1,3	2,1	7,10	9,70	14,60	38,60
M	3	20	0,6	1,3	3,20	4,60	7,10	22,10
M	4	20	0,7	1,5	2,78	3,64	4,94	10,60
M	4	22	5,7	8,26	22,30	28,70	48,50	100,40
M	7	22	2,7	4,22	14,60	19,37	27,30	60,70
F	6	20	1,56	3,12	14,80	20,80	33,60	92,70
F	7	22	3,9	6,2	15,60	20,40	30,40	87,90
F	10	20	2,95	5,5	16,70	22,60	33,60	95,80
M	9	20	3,7	6,6	23,4	32,4	47,9	120,8
M	6	20	1,33	2,28	6,5	9,1	12,8	35,6
F	9	20	6,1	10,4	36	51,6	84,1	208
F	5	20	1,17	2	3,6	6,1	8,9	29,6
F	4	20	1,65	2,8	8,1	11,1	16,2	39,5
F	10	20	1,7	2,6	7,7	10,6	15,7	41,8
F	10	20	2,5	4,7	17	15,8	45,1	132
F	6	20	1,6	2,4	8,40	12,00	18,20	42,10
M	9	20	4,1	7,7	19,50	27,80	16,10	66,30

Summary

- ✓ SIMT DCA SRS is a fast and effective approach for patients with up to ten brain metastases.
- ✓ Using the ExacTrac X-Ray 6D imaging system, the impact of residual translational and rotational errors on target coverage is modest.
- ✓ A GTV-to-PTV margin of 1 mm permits to avoid loss target coverage, although smaller margins may be used for treating lesions within a few centimeters (< 4 cm) to the plan isocenter without decreasing the accuracy and precision of the treatment.
- ✓ The neurocognitive outcome of treatments with regard to the number and total volume of lesions needs to be evaluated in future clinical studies.

Thank you for your attention

